{
  "id": 8572886,
  "title": "XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial",
  "url": "https://urgent.news/2026/09/18/xene-stock-plummets-as-xenon-pharmaceuticals-pauses-drug-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T19:00:04.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/xene-stock-plummets-xenon-pharmaceuticals-190004522.html"
  },
  "original_language": "en",
  "account": "On Friday, the stock price of Xenon Pharmaceuticals (XENE) plummeted after the company announced a pause in new patient enrollment for its clinical trials of azetukalner. The biopharmaceutical firm revealed emerging reports of adverse neuropsychiatric side effects during patient monitoring, a setback for its lead drug candidate in the treatment of major depressive disorder. As a result, the Relative Strength Index (RSI) for XENE shares fell into the early teens, signifying extremely oversold conditions. Currently, the stock is trading approximately 40% below its year-to-date high. Despite this decline, Bank of America considers XENE shares a \"generational entry point\" in U.S. bonds. Mark Cuban, however, shared that he suffered from dizziness for months and built a VR fix to alleviate the issue. JPMorgan has halted its Iran war endgame forecasting due to uncertainty surrounding the situation.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}